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Abstract: Objective: Historically, a set of 5 Cardiovascular Autonomic Reflex Tests (CARTs) were con-
sidered to be the gold standard in the assessment of Cardiovascular Autonomic Neuropathy (CAN). How-
ever, measuring diastolic Blood Pressure (BP) response to sustained handgrip is omitted in recent guide-
lines. We aimed to assess the association between the handgrip and the other 4 tests as well as to identify 
determinants of the handgrip test results in diabetic patients. 
Patients and Methods: 353 patients with diabetes (DM) were recruited (age: 60.2±7.4 years; female: 
57.2%; BMI: 29.3±2.1 kg/m2; DM duration: 15.6±9.9 years; HbA1c: 7.8±1.4% (66 mmol/mol); with type 
1 DM: 18.1%). CAN was assessed by 5 CARTs: the deep breathing test, Valsalva ratio, 30/15 ratio, 
handgrip and orthostatic hypotension test. 
Results: Sensitivity and specificity of the handgrip test in the diagnosis of definite CAN were 24.6% 
(95%CI 17.7-33.1%) and 79.4% (95%CI 73.3-84.4%), respectively. Results of the handgrip test did not 
show any association with those of the deep-breathing test (=0.004, p=0.563), 30/15 ratio (=0.282, 
p=0.357), Valsalva ratio (=-0.058, p=0.436) and orthostatic hypotension (=-0.026, p=0.833). Handgrip 
test abnormality showed an independent association with higher initial diastolic BP (OR 1.05, p=0.0009) 
and an independent inverse association with the presence of hypertension (OR=0.42, p=0.006).  
Conclusion: Our data confirm that the handgrip test should no longer be part of the cardiovascular auto-
nomic testing being highly dependent on hypertensive status and baseline diastolic BP. Exaggerated exer-
cise pressor response is proposed as putative mechanism for the inverse association between abnormal 
results of the handgrip test and hypertension. Adequate CARTs are important to allow their use in clinical 
trials and for the prevention of DM-associated complications by initiating early treatment. 
Keywords: Diabetes, cardiovascular autonomic neuropathy, handgrip test, hypertension. 
INTRODUCTION  
 Cardiovascular Autonomic Neuropathy (CAN) is a 
common complication of diabetes mellitus (DM). Its preva-
lence varies between 7 and 65% depending on the diagnostic 
criteria and the studied population increasing with age and 
DM duration [1]. Moreover, it may be present in newly di-
agnosed patients with type 1 and type 2 DM and in patients 
with impaired glucose tolerance [2]. A meta-analysis of 15 
longitudinal studies with a follow-up of 1-16 years showed  
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that the definite diagnosis of CAN based on at least 2 ab-
normal test results is accompanied by a relative risk of mor-
tality of 3.65 [3]. The association between CAN and cardiac 
death, non-fatal myocardial infarction and silent ischaemia is 
well-known [4]. CAN was associated with left ventricular 
dysfunction and hypertrophy in patients with DM type 2 in 
whom cardiac disease was absent [5]. QT prolongation may 
lead to severe ventricular arrhythmias and a 2-fold risk of 
stroke [5]. There is emerging evidence that CAN is an inde-
pendent predictor of the development and progression of 
diabetic nephropathy [6, 7]. 
 Therefore, early diagnosis of CAN and thereby identify-
ing patients at high risk of cardiovascular morbidity and 
mortality is crucial. In clinical practice, assessment of CAN 
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is usually based on the Cardiovascular Reflex Tests 
(CARTs) standardized by Ewing et al. [8]. CARTs are safe, 
non-invasive, clinically relevant, reproducible and easy-to-
perform. Hence, they are widely used and considered gold 
standard measures of CAN [9, 10]. The San Antonio Con-
sensus conference advocated that a battery of quantitative 
tests including both parasympathetic and sympathetic func-
tion tests should be performed and more than one of these 
tests should be abnormal to verify the diagnosis of CAN 
[10]. The need to use more tests has been confirmed in re-
cent guidelines [1, 11]. However, measuring diastolic blood 
pressure (BP) response to sustained handgrip is no longer 
recommended as an established clinical test [1, 9]. Accord-
ing to the Therapeutics and Technology Assessment Sub-
committee of the American Academy of Neurology, the 
handgrip test has limited sensitivity and specificity in diag-
nosing CAN [9]. Furthermore, little attention has been paid 
to confounding variables influencing the result of handgrip 
test and evidence is lacking to judge its clinical usefulness. 
 The aim of our study was to assess the diagnostic value 
of the handgrip test in detecting CAN. Furthermore, we 
evaluated the relationship of handgrip test results with results 
of the other CARTs and investigated the factors influencing 
the diastolic BP response to sustained handgrip exercise in 
patients with DM. 
RESEARCH DESIGN AND METHODS 
 The present cross-sectional study was carried out in pa-
tients with DM attending the 1st Department of Medicine, 
Semmelweis University, Budapest, Hungary. Inclusion crite-
ria were the presence of type 1 or type 2 DM according to 
the WHO (1999) criteria [12]. Patients hospitalized for acute 
intercurrent diseases (fever, infection, etc.) or for acute 
metabolic derangements such as diabetic ketoacidosis or 
hyperglycaemic hyperosmolar state were excluded from our 
study. Further exclusion criteria included diseases or condi-
tions that may affect autonomic function, such as thyroid and 
liver diseases, chronic kidney failure, autoimmune or haema-
tological disorders, Parkinson’s disease, etc. Subjects with a 
history of arrhythmia, bundle branch block, heart failure, 
valvular disease, acute coronary syndrome, ischaemic heart 
disease or pulmonary disorders (COPD) were also excluded. 
Patients with DM with poor physical status making them 
unable to perform sustained isometric muscular strain and 
patients with proliferative retinopathy being at risk of in-
traocular haemorrhage during Valsalva and handgrip ma-
noeuvre were also not included. 
 Eligible patients were requested to avoid strenuous 
physical exercise, caffeine beverages, smoking and alcohol 
in the 12h preceding cardiovascular autonomic testing. Pa-
tients taking antihypertensive agents that might influence the 
results of the CARTs based on heart rate changes were asked 
to omit interfering medication, particularly beta-receptor 
blockers and non-dihydropyridine-type calcium channel 
blockers in the 24h interval before CARTs were performed. 
 All participants gave informed consent and the study 
protocol was approved by the local ethics committee. 
 Data on age, glycaemic control (HbA1c), DM duration, 
antidiabetic and antihypertensive medication, insulin treat-
ment, use of diuretics and presence of neuropathic pain re-
quiring specific pain-relieving medication were obtained. 
Weight and height of eligible subjects were measured and 
Body Mass Index (BMI) calculated (expressed in kg/m2). 
Measurements of office BP and BP values during the ma-
noeuvres were accomplished using an OMRON M2 (Omron 
Corporation, Kyoto, Japan) automatic upper hand-cuff 
sphygmomanometer. Office BP values were obtained after a 
minimal period of 5 min of resting state and the average of 
three seated BP measurements was determined.
 Cardiovascular autonomic function was assessed by the 5 
CARTs using Cardiosys 12.1 diagnostic station and Cardio-
sys-A01 software (MDE Heidelberg GMBH, Heidelberg, 
Germany). During real-time 12-lead monitoring recorded 
ECG signals were digitized at 2000 Hz sampling rate with a 
multichannel data acquisition system connected to a personal 
computer. Stored data were available for off-line analysis. 
 CARTs based on heart rate changes mainly reflect para-
sympathetic function while those based on BP response to 
manoeuvres explore sympathetic function. 
 The result of the deep-breathing test was expressed as the 
difference of the highest heart rate during inspiration and the 
lowest heart rate during expiration (beat-to-beat variation; 
beats/min). 
 Valsalva ratio was assessed as follows: participants were 
instructed to blow into the mouth piece of Cardiosys con-
nected to the computer and to maintain 40 mmHg airway 
pressure for a period of 15 sec according to the standardised 
protocol. The ratio of the longest RR interval after and the 
shortest RR interval during the manoeuvre was measured. 
 Result of the Orthostatic Hypotension Test (OHT) was 
defined as the difference between the systolic BP measured 
at rest in supine position and the lowest systolic BP after 
arising.
 30:15 ratio was computed as the ratio of the RR intervals 
of the 30th and 15th (or nearby) cycles following standing 
up. 
 Subjects performed sustained handgrip exercise at 30% 
of maximal voluntary contraction up to 3 min. BP values 
were measured before the test (initial or baseline diastolic 
BP) and each minute in the 3 min period during sustained 
handgrip exercise. 
 To evaluate severity of cardiovascular autonomic dys-
function, an overall autonomic neuropathy score (CAN 
score) was obtained by scoring the results of the reflex tests: 
0, 1 and 2 for normal, borderline and abnormal test result, 
according to age-related reference values for heart rate based 
tests [13].  
 Similarly, a parasympathetic impairment score was de-
rived from the results of the parasympathetic function tests 
based on heart rate changes [1]. Normal results of a test were 
scored with 0, borderline results with 1, and abnormal results 
with 2. 
 Confirmed diagnosis of CAN was defined as the pres-
ence of 2 abnormal test results as recommended by recent 
guidelines [13]. 
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Statistical Analysis 
 The Kolmogorov-Smirnov test for normality was per-
formed on all variables. Normally distributed data are ex-
pressed as mean ± SD while non-normally distributed vari-
ables are described as median/geometric mean and interquar-
tile range.  
 To evaluate the diagnostic accuracy of the handgrip test 
vs. diagnosis of confirmed CAN (presence of 2 different 
abnormal test results), sensitivity and specificity were deter-
mined using 2x2 contingency tables and 2 test. Categorical 
variables are reported as n (%). 
 Since most results of CARTs were not normally distrib-
uted, association between the results of the handgrip test and 
clinical parameters were analysed using Spearman’s rank 
correlation (rho). Kruskal’s monotony coefficient gamma 
(), also known as the Goodman-Kruskal test, was used to 
evaluate the association between abnormality of the handgrip 
test and abnormality of the other tests. For comparison be-
tween groups with normal and abnormal handgrip test result, 
the Mann-Whitney U-test or paired t-test for continuous 
variables and 2 test or Fisher’s exact test for categorical data 
were performed as required. 
 In order to adjust for the confounding effect of antihyper-
tensive medication on the association between handgrip test 
results and hypertension as well as the association between 
handgrip test results and initial diastolic BP, additional mul-
tiple logistic regression analysis was performed. Variables 
associated (p <0.1) with abnormal handgrip test result were 
included in this analysis. 
 All analyses were performed using STATISTICA 12.5 
software (Statsoft Inc, Tulsa, USA). Statistical significance 
was defined as p <0.05 (two-sided value). 
RESULTS 
 A total of 353 diabetic patients were included: 64 (18%) 
with type 1 and 289 (82%) with type 2 DM; 225 (63.7%) pa-
tients had coexistent hypertension (30 with type 1 and 195 
with type 2 DM). Hypertensive subjects had known hyperten-
sion and were taking antihypertensive medication. The main 
characteristics of the study population are shown in Table 1.
 Diagnosis of CAN was present in 36.8% of the patients. 
Abnormal results of the deep-breathing test, the Valsalva 
ratio, 30/15 ratio, handgrip and orthostatic hypotension test 
were proven in 59.5, 19.5, 4.5, 22 and 32.3%, respectively.  
 Compared with the definition of CAN based on the pres-
ence of at least 2 abnormal reflex tests, sensitivity of the 
handgrip test for detecting CAN was 24.6% (95% CI 17.7 - 
33.1%) and specificity was 79.4% (95% CI 73.3 - 84.4%) (p 
= 0.384). Abnormal results of the handgrip test did not show 
any association with abnormality of the deep-breathing test 
( = 0.004, p = 0.563), Valsalva ratio ( = - 0.058, p = 
0.436), 30/15 ratio ( = 0.282, p = 0.357) and the parasympa-
thetic impairment score ( = 0.059, p = 0.465), respectively. 
An association between results (scores) of the handgrip and 
the OHT failed to be proven ( = - 0.026, p = 0.833) (Table
2). For comparison, associations of the three parasympathetic 
tests, as well as parasympathetic score with OHT are also 
shown in Table 2.
Table 1. Main clinical characteristics of the study population.
Parameters (n=353)
Mean age (years) 60.2±7.4*
Gender (male/female) 151/202
HbA1c
7.8±1.4% (61.2±15.8 
mmol/mol)*
Diabetes duration (years) 15.6±9.9*
Type 1 / type 2 diabetes 64 (18%) / 289 (82%)
BMI (kg/m2) 28.7 (25; 32)#
Hypertension (yes/no) 225 (63.7%) / 128 (36.3%)
Antihypertensive medication (n=225)
ACEi or ARB/CCB/Diuretics/AG
174/87/151/40
Statin use 160/353 (45%) 
Aspirin use 147/353 (42%) 
* mean ± SD 
# geometric mean (interquartile range). 
ACEi: ACE Inhibitors; ARB: Angiotensin Receptor Blockers,; CCB: Calcium Channel 
Blocker. diuretics included hydrochlorothiazide and indapamide. AG: Alpha1-Receptor 
antagonists. 
 In order to identify factors influencing handgrip test re-
sults, patients with and without handgrip test abnormality 
were compared in terms of demographic and clinical charac-
teristics. Patients with abnormal handgrip test result had sig-
nificantly higher mean office systolic BP (140 vs. 130 
mmHg, p = 0.007) and higher mean baseline diastolic BP (83 
vs. 76 mmHg, p = 0.0004) than those with normal handgrip 
test result. In contrast, diagnosis of hypertension was more 
frequent in patients without handgrip test abnormality [186 
(67.7%) vs. 39 (50%), p = 0.0076] (Table 3).  
 Diastolic BP changes during handgrip test correlated 
negatively to baseline diastolic BP values (rho = - 0.286, p < 
0.01), while office systolic BP had no effect (rho = - 0.0169, 
NS) on the scale of BP increase during handgrip test. In mul-
tiple logistic regression analysis, handgrip test abnormality 
was related to the initial diastolic BP values (OR: 1.05, 95% 
CI: 1.02 - 1.08; p = 0.0009) and inversely related to the pres-
ence of hypertension (OR: 0.42, 95% CI: 0.23 - 0.78, p = 
0.006), with these relationships being independent of anti-
hypertensive medication (Table 4). 
 Abnormal results of the OHT test (defined as a systolic 
BP fall of at least 20 mmHg) were influenced neither by 
clinical characteristics such as age (rho = 0.059, NS), BMI 
(rho = 0.122, NS), DM duration (rho = - 0.102, NS), HbA1c 
(rho = - 0.139, NS), baseline systolic BP (rho = - 0.109, NS) 
nor by the presence of hypertension ( = 0.042, NS). 
DISCUSSION  
 The objectives of our study were to assess the relation-
ship of handgrip with the other CARTs in the diagnosis of 
CAN as well as to identify the factors having influence on 
the diastolic BP response to sustained handgrip. 
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Table 2. Associations between abnormality (i.e. score) of the handgrip test and the abnormalities of the other cardiovascular reflex 
tests (CARTs; for comparison, associations of orthostatic hypotension test (OHT) are also indicated). 
CARTs Scores Handgrip Score p
Deep Breathing  = 0.04 0.563
Valsalva manoeuvre  = 0.058 0.436
30/15 ratio  = 0.282 0.357
Orthostatic hypotension  = -0.026 0.833
Parasympathetic score  = 0.059 0.465
 OHT score p 
Deep Breathing  = 0.219 0.046 
Valsalva manoeuvre  = 0.311 0.006 
30/15 ratio  = 0.470 0.059 
Parasympathetic score  = 0.301 0.003 
 = Monotony coefficient gamma 
Table 3. Comparison of demographic and clinical characteristics of diabetic subjects with or without handgrip test abnormality 
(univariate analysis).
 Abnormal Handgrip Test Result (n=78) Normal Handgrip Test Result (n=275) p
Age (years) 58.8±12.6 60.6±12.5 0.224* 
BMI (kg/m2) 29.0±6.3 29.4±5.8 0.517* 
Diabetes duration (years) 10.9 (8; 20) 10.0 (6; 20) 0.573 
HbA1c (%) 7.8 ±1.4 7.7±1.5 0.340* 
HbA1c (mmol/mol) 61.2±15.8 60.9±15.8 0.338* 
Confirmed diagnosis of CAN 32 (41.0%) 98 (36.6%) 0.384 # 
Deep Breathing (1/min) 8.94 (7; 13) 8.54 (6; 12) 0.510 
Valsalva ratio 1.27 (1.18; 1.32) 1.24 (1.17; 1.32) 0.507 
30/15 ratio 1.15 (1.09; 1.22) 1.17 (1.1; 1.22) 0.542 
Orthostatic hypotension (mmHg) 6 (0; 12) 7 (2; 14) 0.988 
Parasympathetic score 2.94 (2; 4) 2.8 (2; 4) 0.527 
CAN score 3.33 (3; 4) 3.21 (2; 4) 0.468 
Diagnosis of hypertension 39 (50.0%) 186 (67.7%) 0.0076 # 
Office systolic blood pressure (mmHg) 140 (126; 152) 130 (120; 144) 0.007 
Baseline diastolic blood pressure (mmHg) 83 (76; 92) 78 (72; 86) 0.0004 
ACEi/ARB 43 (55.0%) 183 (66.5%) 0.087 # 
CCB 22 (28.2%) 65 (23.6%) 0.836 # 
Alfa receptor antagonist 7 (8.97%) 37 (13.5%) 0.023** 
Diuretics 25 (32.1%) 104 (37.8%) 0.046 # 
Insulin therapy 37 (47.4%) 134 (48.7%) 0.951 # 
Neuropathic pain 11 (14.0%) 35 (12.7%) 0.690 # 
Data are reported as mean + SD or geometric mean/median and interquartile range. Between-group comparisons were carried out by Mann-Whitney U-test or two-sample t-test (*) 
where appropriate. 
# -test or **Fisher’s exact test for categorical variables were used as indicated. Categorical data are reported as n (%). 
Abbreviations: 
BMI: Body Mass Index 
HbA1c: Haemoglobin A1c 
CAN: Cardiovascular Autonomic Neuropathy 
ACEi/ARB: Angiotensin-Convertase Enzyme Inhibitor/Angiotensin Receptor Blocker 
CCB: Calcium Channel Blocker 
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Table 4. The relationship between handgrip test abnormality and hypertension as well as initial diastolic blood pressure values
adjusted for the confounding antihypertensive medication (multiple logistic regression analysis). 
 Variables p <0.1 from table 4 are included in the analysis.  
OR 95% CI p 
Hypertension 0.42 0.23-0.78 0.006 
ACEi/ARB 0.96 0.49-1.84 0.909
Alpha-receptor antagonists 1.04 0.42-2.59 0.931 
Diuretics 1.14 0.61-2.13 0.696 
Initial diastolic blood pressure 1.05 1.02-1.08 0.0009 
Abbreviations: ACEi/ARB: angiotensin-convertase enzyme inhibitor/angiotensin receptor blocker. 
 According to our data, very low sensitivity and moderate 
specificity of the handgrip test vs. definite diagnosis of CAN 
could be demonstrated. Results of the handgrip test did not 
show any association with results of the deep breathing test, 
30/15 ratio and the partially sympathetically controlled Val-
salva ratio. An association between results of the handgrip 
test and the OHT could not be proven. Potential confounding 
factors having influence on handgrip test outcomes were the 
presence of hypertension and baseline diastolic BP. 
 CAN is an early and frequent complication and is ac-
companied with poor prognosis among patients with DM. In 
epidemiological studies performed on patient populations 
with both type 1 and type 2 DM, the prevalence rates of con-
firmed CAN ranged from 16.6 to 20% [14, 15]. The preva-
lence of CAN increases with age and DM duration reaching 
as high as 65% in patients with long-standing type 2 DM 
[16]. In our study, the prevalence rate of CAN based on the 
presence of 2 abnormal cardiovascular reflex tests was 
37%. Considering age, DM duration and the proportion of 
type 2 DM patients in our study population, this prevalence 
is in accordance with the literature [1, 3, 6, 11, 13-14]. 
 As CAN imposes an enormous increase in cardiovascular 
morbidity and mortality among patients with DM, early di-
agnosis and timely intervention with risk reduction strategies 
are crucial. Safe, non-invasive tests with high sensitivity and 
reasonable specificity are warranted. Cardiovascular reflex 
tests are widely used for identifying patients with CAN. In a 
study by Ewing et al. [17], a weak but significant correlation 
between the rise in diastolic BP in response to handgrip and 
Valsalva ratio was demonstrated. Patients with handgrip test 
abnormality had lower Valsalva ratio compared with those 
with normal handgrip test results [17]. When compared with 
spectral analysis of heart rate variability as a reference test, 
BP tests added on to heart rate tests did not improve diagnos-
tic performance of CARTs [18]. Sustained handgrip test had 
significant weaker associations with LnLFDAY – a measure of 
prevalent sympathetic function – than OHT did [18]. How-
ever, particular reasons why the handgrip test has limited 
diagnostic performance remained elusive.  
 In the present study, we confirmed that handgrip test has 
poor sensitivity and moderate specificity for diagnosing 
CAN. No associations between handgrip test results and 
other CART outcomes could be established. Furthermore, a 
negative association between handgrip test abnormality and 
hypertension was demonstrated showing that patients with 
both DM and hypertension are unlikely to exhibit reduced 
diastolic BP response to handgrip exercise. The putative 
mechanism behind this phenomenon could be an exaggerated 
exercise pressor reflex related to increased sympathetic acti-
vation in patients with DM and hypertension. 
 The exercise pressor reflex aims the adaptation of auto-
nomic nerve control of the cardiovascular system during 
exercise to meet the perfusion and metabolic demand of 
working skeletal muscle. Static (isometric) exercise causes 
heart rate-dependent increases in cardiac output accompa-
nied by increased or unchanged peripheral vascular resis-
tance resulting in substantially elevated BP [19, 20]. There is 
emerging evidence that hypertension is associated with ex-
cessive pressor responses during muscle contraction; both 
mechanically (mechanoreflex) and metabolically (metabore-
flex) driven components of the pressor reflex are suggested 
being involved [21, 22]. Patients with hypertension were 
shown to produce exaggerated BP elevation and enhanced 
muscle sympathetic nerve activation during isometric hand-
grip exercise compared with age-related healthy controls [23, 
24]. Increased muscle metaboreflex activation leading to 
augmented pressor responses was demonstrated in older 
moderately hypertensive adults [25] and in pre-hypertensive 
state [26]. The exercise pressor reflex might occur promptly: 
BP elevation and heart rate increased within 30-60 sec dur-
ing static contraction in an experimental study [27]. More 
than two-thirds of our patients with DM had hypertension; 
this exaggerated exercise pressor reflex might explain why 
abnormal handgrip test results were not commonly found in 
our patients, even if they may have been already affected by 
CAN. The inverse association between abnormality of the 
handgrip test and hypertension indicates that low sensitivity 
of the handgrip test might be the result of a ‘masking effect’ 
of hypertension. 
 Previously, both hypertension and DM were found to be 
associated with impaired autonomic function: they nega-
tively influence most CARTs [28], baroreflex sensitivity and 
heart rate variability [29-31] with their effects being additive 
[32, 33]. Nevertheless, the handgrip test seems to be the only 
measure of CAN being conversely affected by DM and hy-
pertension. Hence, handgrip test outcomes might reflect the 
counteraction between increased sympathetic activity being a 
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feature of essential hypertension and sympathetic impair-
ment attributable to diabetic autonomic neuropathy. 
 Hypertension is a frequent comorbidity of DM. Using 
ambulatory BP monitoring (ABPM), hypertension could be 
diagnosed in 54 and 29% of type 2 DM patients with/without 
CAN in spite of normal office BP and no history of hyper-
tension [30]. In this context, hypertension may remain un-
recognized in up to half of the patients with CAN [30]. 
Therefore, the effects of hypertension on handgrip test re-
sults cannot be overestimated in routine clinical practice. The 
known or unknown hypertension involving sympathetic 
overactivity prevents detecting CAN in the majority of our 
patients when sympathetic dysfunction is assessed by the 
handgrip test. 
 Autonomic dysregulation characterized by sympathetic 
overactivity and parasympathetic impairment has been pro-
posed as a mechanism of developing hypertension [34]. The 
role of baroreflex in attenuating the circulatory response to 
exercise has been recently described [35]. Consequently, one 
could speculate that augmented BP response to sustained 
muscular strain and hypertension itself may be at least par-
tially compelled by parasympathetic impairment leading to 
‘pseudo-normal’ handgrip test results in patients with dia-
betic neuropathy. 
 In our study, diastolic BP changes in response to hand-
grip test were inversely correlated with baseline diastolic BP. 
The higher the baseline values were, the less was the extent 
of diastolic BP elevation and the greater was the chance of 
handgrip test abnormality. It would be conceivable that base-
line diastolic BP is a limiting factor of diastolic BP increase 
during the test. Noteworthy, reduced diastolic BP as a conse-
quence of increased central artery stiffness is a common fea-
ture of hypertension in the elderly. Hence, the association 
between lower diastolic BP and normal handgrip test results 
may be also attributed to atherosclerosis and hypertension in 
our population. Still, the independent association between 
higher baseline diastolic BP values and handgrip test abnor-
mality needs further investigation. 
 The strength of the present study is the well-defined pa-
tient population. All drugs, especially antihypertensive 
agents being of potential influence on the outcomes of the 
cardiovascular reflex tests were included in the statistical 
analysis. Therefore, an independent inverse association be-
tween abnormality of the handgrip test and the presence of 
hypertension could be revealed. 
 A limitation of this study could be the absence of infor-
mation on physical activity. Muscle function might influence 
the pressor response during isometric exercise. However, the 
exclusion of patients with relevant comorbidities and poor 
physical status should have excluded those with significantly 
impaired muscle function. Moreover, overweight status of 
our patients was only assessed by calculating BMI that does 
not provide any information on the type of obesity. Visceral 
adipose tissue accumulation may contribute to sympathetic 
nervous system activation [36, 37]. Although no association 
between handgrip test results and BMI was found, the influ-
ence of visceral obesity on our results cannot be entirely ex-
cluded.  
 The OHT test results were associated with measures of 
all three parasympathetic function tests, including the Val-
salva ratio, confirming previous observations [38]. The asso-
ciation between OHT and abnormal Valsalva ratio is plausi-
ble, as OHT is an established test of sympathetic function as 
well, and circulatory changes during the Valsalva manoeuvre 
are also partially controlled by sympathetic pathways. The 
former association may be attributable to the fact that the 
possibility and extent of sympathetic impairment is expected 
to increase with severity of parasympathetic dysfunction. 
OHT was independent of anthropometric data and was nei-
ther influenced by the presence of hypertension nor by initial 
supine systolic BP suggesting that it is a reliable test. This 
latter finding is in contrast with previous observations that 
the magnitude of the orthostatic BP fall is related to the base-
line supine BP with 25% of the variance of the systolic BP 
fall being due to the supine BP [38, 39]. This discrepancy 
might be explained by the fact that systolic BP values in our 
patients were not very high and they were treated with anti-
hypertensive medication. 
 This topic has several important therapeutic implications. 
Alpha-lipoic acid, the most powerful pathogenetic therapeu-
tic option of diabetic peripheral neuropathy [40-42] is also 
considered as the best choice for the treatment of CAN [43]. 
Alpha-lipoic acid enhances endoneurial blood flow by pre-
venting the inhibition of nitric oxide synthetase and this way 
precludes ischaemic damage to nerve tissues [41]. Another 
pathogenetic option is the transketolase activator benfotia-
mine, inhibiting harmful alternative metabolic pathways, 
such as advanced glycation end product formation, the 
hexosamin and the protein-kinase-C pathways [44], as well 
as the polyol pathway [45].  
 Our data indicate that the presence of hypertension was 
identified as the main confounder for the presence of a false 
negative handgrip test. The majority of patients with DM, 
especially those with autonomic neuropathy, have hyperten-
sion as well [30, 32, 36, 46, 47]. Most patients with DM and 
hypertension are treated with ACE inhibitors, while these 
drugs might have an effect on autonomic function as well. 
Didangelos et al. [48] assessed the effect of ACE inhibition 
or angiotensin receptor blockade, and their combination on 
CAN in patients with DM. After 12 months, improvement of 
CAN was observed in patients treated both with quinapril or 
losartan, while their combination was slightly even more 
effective [48]. Beneficial effect of quinapril on CAN has also 
been observed in another study [49], while no significant 
changes in CAN was detected after 12 months treatment with 
trandolapril [50]. 
 In the context of parasympathetic-sympathetic imbalance, 
relative sympathetic overactivity influences the action of 
beta-blocking agents; cardioselective beta-blockers have a 
beneficial effect on cardiac autonomic dysfunction [51]. Our 
results confirm that assessment of orthostatic BP changes 
should be considered as the only reliable measure of sympa-
thetic nerve function. Some drugs, like hydrochlorothiazide, 
alpha- and non-selective beta-blocking agents might aggra-
vate OHT, while beta-blockers with intrinsic sympath-
omimetic properties (partial agonists) have a role in the ther-
apy of OHT. 
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 In summary, the handgrip test has low sensitivity for 
CAN and shows no association with the other reflex tests 
established for assessing CAN in DM. Our data provide evi-
dence that the handgrip test should no longer be part of the 
cardiovascular autonomic testing being highly dependent on 
both the hypertensive status and baseline diastolic BP. 
Among these factors, the presence of hypertension seems to 
be decisive. Instead of measuring diastolic BP response to 
handgrip exercise, OHT test should be used for the evalua-
tion of sympathetic dysfunction as recommended in the latest 
guidelines [1]. 
 Adequate CARTs are important to allow their use in 
clinical trials and for the prevention of DM-associated com-
plications by initiating early treatment.  
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